Sign In
19 Apr 2023 07:00
Director's Dealing
ย
ย
Guildford, UKย - 19 April 2023: Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announces thatย on 19 April 2023, Drย Miroslav Reljanoviฤ, Executive Chairman of Ergomed, transferred 400,000 ordinary shares of 1p each in the Company ("Ordinary Shares") to a former director of the Company. The transferย took place following an exercise of options under an option agreement dated 5 August 2019 between Dr Reljanoviฤ and the former director and the exercise price was 1p per ordinary share.
ย
Following the transfer,ย Dr Reljanoviฤย holds 9,129,297 ordinary shares representing 17.98%ย of the Company's issued share capital.
ย
The relevant notifications set out below are provided in accordance with the requirements of Article 19 of theย UKย Market Abuse Regulation.
ย
ย
1 | Details of the person discharging managerial responsibilities/person closely associated | ||
a) | Name | Dr Miroslav Reljanoviฤ | |
2 | Reason for the notification | ||
a) | Position/status | Executive Chairman | |
b) | Initial notification /Amendment | Initial Notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Ergomed plc | |
b) | Legal Entity Identifier | 213800BVS8I9VMC1AP84 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument ย Identification code | Ordinary shares ofย 1 penceย each ย ย ย GB00BN7ZCY67 | |
b) | Nature of the transaction | Transfer of shares | |
c) | Currency | GBP | |
d) | Price(s)ย andย volume(s) | Price(s) | Volume(s) |
ยฃ0.01 | 400,000 | ||
ย | ย | ||
e) | Aggregated information ย - Aggregated volume ย - Price ย - Aggregated total | ย ย 400,000 ย ยฃ0.01 ย ยฃ4,000 ย ย | |
f) | Date of the transaction | 19 April 2023 | |
g) | Placeย ofย theย transaction | London Stock Exchange, AIM | |
ย
ย
ย
ย
ENDS
ย
Enquiries:
Ergomed plc | ย Tel: +44 (0) 1483 402 975 |
Miroslav Reljanoviฤ (Executive Chairman) | |
Jonathan Curtain (Chief Financial Officer) Keith Byrne (Senior Vice President, Capital Markets and Strategy) | |
Numis Securities Limited (Nominated Adviser and Joint Broker) | Tel: +44 (0) 20 7260 1000 |
Freddie Barnfield / Euan Brown / Jack McLaren | |
ย Peel Hunt Securities Limited (Joint Broker) James Steel / Dr Christopher Golden | ย ย Tel: +44 (0) 20 7418 8900 ย |
Consilium Strategic Communications - for UK enquiries | Tel: +44 (0) 20 3709 5700 |
Chris Gardner / Matthew Neal | ergomed@consilium-comms.com |
ย
About Ergomed plc
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO) and mission-critical regulatory compliance and consulting services under the ADAMAS brand. For further information, visit: http://ergomedplc.com.
Follow the stocks
